Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Abroad (travel likely)RecruitingPHASE1

Conditions

CD30-Positive Diffuse Large B-Cell Lymphoma · Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type · Anaplastic Large Cell Lymphoma, ALK-Positive · Peripheral T-cell Lymphoma · Anaplastic Large Cell Lymphoma, ALK-negative · Non-Hodgkin Lymphoma · Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Houston Methodist Hospital, Houston, Texas, United States
Contact: Study coordinator (Premal Lulla, MD) · lulla@bcm.edu · 713-441-1450
Contact: Study coordinator (Vicky Torrano, RN) · vtorrano@bcm.edu · 832-824-7821
Texas Children's Hospital, Houston, Texas, United States
Contact: Study coordinator (Premal Lulla, MD) · lulla@bcm.edu · 713-441-1450
Contact: Study coordinator (Vicky Torrano, RN) · vtorrano@bcm.edu · 832-824-7821

Study leads

Premal Lulla, MD
Principal Investigator
Baylor College of Medicine

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Hodgkin Disease · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30+ Anaplastic Large Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Milwaukee, United States